44
Participants
Start Date
March 22, 2025
Primary Completion Date
December 31, 2026
Study Completion Date
March 31, 2027
Dapagliflozin+Standard Treatment for 12 weeks,washout period for 4 weeks，then Standard Treatment alone for12 weeks
"①Dapagliflozin+Standard Treatment for 12 weeks. Dapagliflozin therapy (Farxiga®, 10 mg tablets) is administered orally once daily,with dose adjustment based on body weight: 5 mg/day for participants ≤30 kg; 5 mg/day initially (first week), then increased to 10 mg/day for participants \>30 kg Standard Treatment:standard renin-angiotensin-aldosterone system inhibitor (RAASi) therapy(The dosage will be maintained at the pre-enrollment level throughout the entire treatment period, with no adjustments made during therapy.),This combined therapy will be administered for 12 weeks.~② Washout period for 4 weeks Participants should maintenance RAASi therapy while discontinuing dapagliflozin.~③Standard Treatment alone for an additional 12 weeks. To ensure compliance, all participants are required to complete a daily medication log.If any adverse events (AEs) occur, appropriate clinical interventions will be promptly implemented"
Standard Treatment alone for 12 weeks ,washout period for 4 weeks ,then Dapagliflozin+Standard Treatment for 12 weeks
"①Standard Treatment for 12 weeks Standard Treatment:Standard renin-angiotensin-aldosterone system inhibitor (RAASi) therapy alone for 12 weeks.(The dosage will be maintained at the pre-enrollment level throughout the entire treatment period, with no adjustments made during therapy.)~②Washout period for 4 weeks Participants should maintenance RAASi therapy while discontinuing dapagliflozin.~③Dapagliflozin+Standard Treatment for 12 weeks Dapagliflozin therapy (Farxiga®, 10 mg tablets) is administered orally once daily,with dose adjustment based on body weight: 5 mg/day for participants ≤30 kg; 5 mg/day initially (first week), then increased to 10 mg/day for participants \>30 kg.This combined therapy will be administered for 12 weeks To ensure compliance, all participants are required to complete a daily medication log.If any adverse events (AEs) occur, appropriate clinical interventions will be promptly implemented"
RECRUITING
Children's Hospital of Fudan University, Shanghai
Guangzhou Women and Children's Medical Center
OTHER
Maternal and Child Health Hospital of Guangxi Zhuang Autonomous Region
OTHER
Shandong Provincial Hospital
OTHER_GOV
The First Affiliated Hospital of Henan University of Traditional Chinese Medicine
OTHER
Wuhan Children's Hospital
OTHER
Xuzhou Children Hospital
OTHER
First Affiliated Hospital, Sun Yat-Sen University
OTHER
Kunming Children's Hospital
OTHER
The Children's Hospital of Zhejiang University School of Medicine
OTHER
Children's Hospital of Nanjing Medical University
OTHER
Zhengzhou Children's Hospital, China
OTHER
Xiamen Women's and Children's Hospital
UNKNOWN
Guiyang Maternity and Child Health Care Hospital
OTHER
Maternal and Child Health Care Hospital of Hainan Province
OTHER
Children's Hospital of The Capital Institute of Pediatrics
OTHER
Second Affiliated Hospital of Wenzhou Medical University
OTHER
Xian Children's Hospital
OTHER_GOV
The Second Hospital of Hebei Medical University
OTHER
Wuxi Women's & Children's Hospital
OTHER
First People's Hospital of Urumqi
UNKNOWN
Children's Hospital of Fudan University
OTHER